Ampio Pharmaceuticals Inc. (AMPE) and ChemoCentryx Inc. (NASDAQ:CCXI) Comparison side by side

Both Ampio Pharmaceuticals Inc. (NYSEAMERICAN:AMPE) and ChemoCentryx Inc. (NASDAQ:CCXI) are Biotechnology companies, competing one another. We will contrast their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ampio Pharmaceuticals Inc. 1 0.00 N/A 0.09 4.57
ChemoCentryx Inc. 11 11.11 N/A -0.80 0.00

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for Ampio Pharmaceuticals Inc. and ChemoCentryx Inc.


Table 2 shows us Ampio Pharmaceuticals Inc. and ChemoCentryx Inc.’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Ampio Pharmaceuticals Inc. 0.00% 0% 0%
ChemoCentryx Inc. 0.00% -111.1% -19.7%

Volatility and Risk

Ampio Pharmaceuticals Inc. has a 0.85 beta, while its volatility is 15.00%, thus making it less volatile than Standard and Poor’s 500. Competitively, ChemoCentryx Inc.’s beta is 1.03 which is 3.00% more volatile than Standard and Poor’s 500.


3.7 and 3.7 are the respective Current Ratio and a Quick Ratio of Ampio Pharmaceuticals Inc. Its rival ChemoCentryx Inc.’s Current and Quick Ratios are 3.4 and 3.4 respectively. Ampio Pharmaceuticals Inc. has a better chance of clearing its pay short and long-term debts than ChemoCentryx Inc.

Analyst Ratings

The following table delivered below contains the ratings and recommendations for Ampio Pharmaceuticals Inc. and ChemoCentryx Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Ampio Pharmaceuticals Inc. 0 0 0 0.00
ChemoCentryx Inc. 0 0 4 3.00

Meanwhile, ChemoCentryx Inc.’s consensus price target is $22.25, while its potential upside is 212.94%.

Institutional & Insider Ownership

Institutional investors held 33.8% of Ampio Pharmaceuticals Inc. shares and 59.6% of ChemoCentryx Inc. shares. Insiders held roughly 10.71% of Ampio Pharmaceuticals Inc.’s shares. Competitively, 4.9% are ChemoCentryx Inc.’s share held by insiders.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Ampio Pharmaceuticals Inc. -4.19% -6.83% -33.78% -22.26% -86.96% -1.55%
ChemoCentryx Inc. 0.25% -10.94% -38.33% -35.49% -28.17% -26.86%

For the past year Ampio Pharmaceuticals Inc. has stronger performance than ChemoCentryx Inc.


Ampio Pharmaceuticals Inc. beats on 6 of the 9 factors ChemoCentryx Inc.

Ampio Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process; and decreasing vascular permeability. Its product pipeline includes Ampion, an intra-articular injection for the treatment of osteoarthritis of the knee; and Optina, which has completed Phase II clinical trials for diabetic macular edema. Ampio Pharmaceuticals, Inc. is headquartered in Englewood, Colorado.

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan (CCX168), an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). The company also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe CrohnÂ’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis. It has a partnership with Vifor (International) Ltd. for the geographic commercial rights of Avacopan in Europe and other international markets. ChemoCentryx, Inc. was founded in 1997 and is headquartered in Mountain View, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.